Fujirebio Expands Neurology Testing Access in Canada
GHENT, Belgium and TOKYO, Japan, September 1, 2026 Fujirebio, a wholly owned subsidiary of H.U. Group Holdings, announced that...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
GHENT, Belgium and TOKYO, Japan, September 1, 2026 Fujirebio, a wholly owned subsidiary of H.U. Group Holdings, announced that...
TOKYO and CAMBRIDGE, Mass., August 31, 2026 Eisai and Biogen announced that Canada’s Drug Agency (CDA-AMC) has issued a...
INDIANAPOLIS, U.S., Aug 28, 2026 Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based...
Tokyo, Japan and Cambridge, UK — August 26, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences...
Tokyo, Japan and Cambridge, Massachusetts, August 25, 2026 Eisai Co., Ltd. and Biogen Inc. announced that LEQEMBI IQLIK® (lecanemab-irmb)...
Secaucus, New Jersey, August 24, 2026 Quest Diagnostics announced new developments in its Quest AD-Detect® blood-testing portfolio, expanding access...
NEW YORK, August 21, 2026 The U.S. Food and Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2 blood test,...
COVINGTON, Ky., August 18, 2026 Cortechs.ai announced that its NeuroQuant® PET platform has received FDA 510(k) clearance (K261916) for...
Stockholm, Sweden, August 18, 2026 AlzeCure Pharma AB has received the full $10 million upfront payment from Eli Lilly...
Malvern, Pennsylvania — August 14, 2026 Annovis Bio, Inc. announced that its pivotal Phase 3 Alzheimer’s disease trial of...
